Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx to Profile Oncology Asset for Pharma Firm

NEW YORK(GenomeWeb) – Horizon Discovery today said that its CombinatoRx division has inked a contract with an unnamed "top 10" pharmaceutical firm to profile a lead oncology asset. 

Horizon CombinatoRx will be paid $750,000 for work completed within a five-month period, it said. The company provides its partners access to the combination high-throughput screening platform and Chalice analytics software for the screening and analysis of thousands of complementary drug combinations. Horizon acquired CombinatoRx in June for $8 million.

Last month, Horizon CombinatoRx announced a similar contract with another undisclosed pharma firm. In July, it signed a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development.